GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Cyclically Adjusted PB Ratio

GLMD (Galmed Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of May. 29, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Galmed Pharmaceuticals's current share price is $1.43. Galmed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $365.63. Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

GLMD's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.485
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galmed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $7.474. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $365.63 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galmed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Galmed Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.20 0.01 0.01

Galmed Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.02 0.01 -

Competitive Comparison of Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Galmed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.43/365.63
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Galmed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=7.474/134.9266*134.9266
=7.474

Current CPI (Mar. 2025) = 134.9266.

Galmed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 442.177 100.684 592.562
201509 404.194 100.392 543.238
201512 347.500 99.792 469.845
201603 288.387 100.470 387.289
201606 232.677 101.688 308.731
201609 231.791 101.861 307.034
201612 165.299 101.863 218.954
201703 122.029 102.862 160.068
201706 91.794 103.349 119.841
201709 92.000 104.136 119.203
201712 197.438 104.011 256.123
201803 170.025 105.290 217.884
201806 784.853 106.317 996.057
201809 775.624 106.507 982.589
201812 751.231 105.998 956.255
201903 725.880 107.251 913.194
201906 695.615 108.070 868.487
201909 661.735 108.329 824.205
201912 597.034 108.420 742.997
202003 543.254 108.902 673.080
202006 507.492 108.767 629.547
202009 454.712 109.815 558.692
202012 374.178 109.897 459.400
202103 380.986 111.754 459.983
202106 323.734 114.631 381.050
202109 271.050 115.734 315.998
202112 219.403 117.630 251.666
202203 175.295 121.301 194.986
202206 149.007 125.017 160.818
202209 112.493 125.227 121.207
202212 95.879 125.222 103.310
202303 85.643 127.348 90.740
202306 75.386 128.729 79.016
202309 46.548 129.860 48.364
202312 33.045 129.419 34.451
202403 25.461 131.776 26.070
202406 22.240 132.554 22.638
202409 12.234 133.029 12.409
202412 9.806 133.157 9.936
202503 7.474 134.927 7.474

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galmed Pharmaceuticals  (NAS:GLMD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galmed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Galmed Pharmaceuticals Headlines

From GuruFocus